Abstract:Osteoarthritis (OA) is a painful and disabling disease that affects millions of people worldwide. Symptom-alleviating treatments exist, although none with long-term efficacy. Furthermore, there are currently no disease-modifying OA drugs (DMOADs) with demonstrated efficacy in OA patients, which is, in part, attributed to a lack of full understanding of the pathogenesis of OA. The inability to translate findings from basic research to clinical applications also highlights the deficiencies in the available OA models at simulating the clinically relevant pathologies and responses to treatments in humans. In this review, the current status in the development of DMOADs will be first presented, with special attention to those in Phase II-IV clinical trials. Next, current in vitro, ex vivo, and in vivo OA models are summarized and the respective advantages and disadvantages of each are highlighted. Of note, the development and application of microphysiological or tissue-on-a-chip systems for modeling OA in humans are presented and the issues that need to be addressed in the future are discussed. Microphysiological systems should be given serious consideration for their inclusion in the DMOAD development pipeline, both for their ability to predict drug safety and efficacy in human clinical trials at present, as well as for their potential to serve as a test platform for personalized medicine. Impact statement At present, no disease-modifying osteoarthritis (OA) drugs (DMOADs) have been approved for widespread clinical use by regulatory bodies. The failure of developing effective DMOADs is likely owing to multiple factors, not the least of which are the intrinsic differences between the intact human knee joint and the preclinical models. This work summarizes the current OA models for the development of DMOADs, discusses the advantages/disadvantages of each, and then proposes future model development to aid in the discovery of effective and personalized DMOADs. The review also highlights the microphysiological systems, which are emerging as a new platform for drug development.

Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development

From biochemical markers to molecular endotypes of osteoarthritis: a review on validated biomarkers

Molecular portrait of chronic joint diseases: defining endotypes toward personalized medicine

Osteoarthritis endotype discovery via clustering of biochemical marker data

Structural phenotypes of knee osteoarthritis: potential clinical and research relevance

Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping

Prospects of Disease-Modifying Osteoarthritis Drugs

Clinical Phenotypes of Hip Osteoarthritis Across the Biopsychosocial Spectrum

Disease progression and clinical outcomes in latent osteoarthritis phenotypes: Data from the Osteoarthritis Initiative

Classification of Osteoarthritis Phenotypes by Metabolomics Analysis

Unraveling the joints: a narrative review of osteoarthritis

Molecular Classification of Knee Osteoarthritis

Current Models for Development of Disease-Modifying Osteoarthritis Drugs

Obesity defined molecular endotypes in the synovium of patients with osteoarthritis provides a rationale for therapeutic targeting of fibroblast subsets

Multi-Omics Integrative Analyses Identified Two Endotypes of Hip Osteoarthritis

Clinical implications of synovial tissue phenotypes in rheumatoid arthritis

Unveiling MRI-based structural phenotypes in temporomandibular joint osteoarthritis: implications for clinical practice and research

[Future Aspects of Clinical Osteoarthritis Therapies in the Continuum of Translational Research].

Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactions

Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy